Dioxolane analogues of uridine for the treatment of cancer
AssigneeMedivir AB
InventorsRichard Bethell, Anders Eneroth, Bjorn Klasson, Fredrik Oberg
Life of this patent
Estimating the term…
Abstract
The invention provides compounds of the formula: R1 is OR11, or NR5R5′; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(═O)R6, O(C═O)R6 or O(C═O)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.
Claims11
A method for the treatment of liver cancer, comprising the oral administration to a warm blooded animal of a therapeutically effective amount of a compound of the formula Ia:
- wherein:
- R1 is NH2;
- R2 is H;
- R13 is phenyl or naphthyl any of which is optionally substituted with 1, 2 or 3 R22;
- R15 is methyl;
- R16 is C3-C7cycloalkyl;
- each R22 is independently selected from halo, C1-C6alkyl, C2-C6alkenyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, phenyl, hydroxyC1-C6alkyl, C3-C6cycloalkyl, C1-C6alkylcarbonyl, C3-C6cycloalkylcarbonyl, carboxyC1-C6alkyl, hydroxy, amino CN, and NO2, or any two R22 groups attached to adjacent ring carbon atoms can combine to form —O—(CR23R23′)1-6—O—;
- R23 and R23′ are independently H or C1-C3alkyl;
- or a pharmaceutically acceptable salt and/or solvate thereof.
Dependencies are inferred from the claim text.